Congratulations to the Northeastern University Student Affiliates of the American Chemical Society for earning the title of Outstanding Student Chapter and Green Chemistry Award from the ACS!
Kenneth Henderson can point to the moment when his career spun in an exciting new direction: a five-month industry placement in London prior to his senior year of college. Here, the new College of Science dean discusses the importance of experiential education and his vision for the college.
Dana Klug, Chemistry PhD candidate, sits down with the College of Science Graduate Program staff to talk about what it’s like to work and study at Northeastern University.
In a recently funded project involving Boston Children’s Hospital and Northeastern University, chemistry Professors John R. Engen and Roxana Iacob have teamed up with Prof. Timothy A. Springer—a renowned immunologist and structural biologist from Harvard Medical School (HMS) and Boston Children’s Hospital—to uncover the inner-workings of an extremely complex class of proteins.
The goal of the joint research is to understand and develop small molecule drugs that target the deubiquitinating enzyme USP-10.
Northeastern University College of Science Dean Kenneth Henderson delivered the opening lecture at the Universities of Scotland Inorganic Chemistry Conference earlier this week, held at the University of Strathclyde in Glasgow, Scotland.
Professor John Engen helped develop a new hybrid technique to study how a critical HIV protein changes shape to allow infected cells to evade the immune system.
John de la Parra has a goal of using his love of plants to find new medicines from indigenous cultural practices and then bring in the full power of modern biotechnology to create a a controllable platform to create the medicines desperately needed for disease.
Derion Reid, Chemistry PhD candidate, sits down with the College of Science Graduate Program staff to talk about what it’s like to work and study at Northeastern University.
Boston is the apex of today’s biotechnology world. With over 250 companies in Boston, Cambridge, and surrounding suburbs, nearly every pharmaceutical company has a stake in Boston’s biotech network.